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Introduction
Erythropoietin (EPO), the blood hormone produced primarily in fetal liver and adult kidneys upon 
hypoxic stimulation, is required for erythrocyte propagation and maturation and functions through 
binding to its specific transmembrane receptor (EpoR) (1). Recombinant human EPO is used clinically 
to treat anemia associated with chronic kidney disease, cancer chemotherapy, or HIV antiretroviral 
therapy. In mice, targeted deletion of  Epo or EpoR gene results in embryonic lethality due to severe 
anemia (2, 3). EpoR signaling in hematopoietic cells is determined by EPO concentration and EpoR 
cell surface expression level. Beyond erythroid progenitor/precursor cells, EpoR expression and EPO 
activity has been detected in nonhematopoietic cells (4, 5), including macrophages (6, 7), osteoclasts 
(8), microglial cells (9), neurons (10), endothelial cells (11), and adipocytes (12). This produces several 
nonerythroid physiological effects of  EPO.
Erythroid transgenic rescue of EpoR-knockout mice (termed ΔEpoRE mice) restores early development and 
erythropoiesis but results in obesity by 4 weeks of age (12). ΔEpoRE mice develop metabolic syndrome with 
increased fat, glucose intolerance, and insulin resistance, resulting from low energy expenditure due primarily 
to effects in white adipose tissue (WAT) and the hypothalamus. ΔEpoRE mice show increased white fat mass 
and adipocyte number (12), reduced hypothalamic expression of anorexigenic neuropeptide pro-opiomelano-
cortin (POMC) (13), and higher serum adrenocorticotropic hormone (ACTH) due to deregulated secretion 
from the pituitary gland (14). Conversely, exogenous EPO treatment in WT mice can prevent diet-induced obe-
sity (DIO), improve glucose tolerance, reduce food intake (12, 15, 16), and shift WAT-associated macrophages 
from a proinflammatory to an antiinflammatory phenotype (6). Male mice are more susceptible to DIO than 
The blood hormone erythropoietin (EPO), upon binding to its receptor (EpoR), modulates high-
fat diet–induced (HFD-induced) obesity in mice, improves glucose tolerance, and prevents white 
adipose tissue inflammation. Transgenic mice with constitutive overexpression of human EPO 
solely in the brain (Tg21) were used to assess the neuroendocrine EPO effect without increasing 
the hematocrit. Male Tg21 mice resisted HFD-induced weight gain; showed lower serum 
adrenocorticotropic hormone, corticosterone, and C-reactive protein levels; and prevented myeloid 
cell recruitment to the hypothalamus compared with WT male mice. HFD-induced hypothalamic 
inflammation (HI) and microglial activation were higher in male mice, and Tg21 male mice exhibited 
a lower increase in HI than WT male mice. Physiological EPO function in the brain also showed 
sexual dimorphism in regulating HFD response. Female estrogen production blocked reduced 
weight gain and HI. Targeted deletion of EpoR gene expression in neuronal cells worsened HFD-
induced glucose intolerance in both male and female mice but increased weight gain and HI in the 
hypothalamus in male mice only. Both male and female Tg21 mice kept on normal chow and HFD 
showed significantly improved glycemic control. Our data indicate that cerebral EPO regulates 
weight gain and HI in a sex-dependent response, distinct from EPO regulation of glycemic control, 
and independent of erythropoietic EPO response.
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female mice, and EPO is more effective in preventing weight and fat gain in males, indicating sexually dimor-
phic EPO regulation of metabolism that may also occur in humans (17, 18).
EPO is also synthesized in the brain, mainly by astrocytes and neurons, is hypoxia inducible, and is 
associated with neural progenitor cell proliferation and differentiation (19–21). EPO has been associated 
with neurogenesis, neuroprotection, and neural progenitor cell migration (21–24). In the hypothalamus, the 
arcuate nucleus is a major central neuroendocrine regulation center controlling energy homeostasis and 
EpoR expression colocalizes with POMC-producing neurons (12, 13). EPO can directly induce POMC 
expression through STAT3 signaling, and lack of  EpoR reduces POMC, contributing to EPO-mediated 
metabolic effects. The hypothalamus communicates with the pituitary gland and processes signals from 
peripheral energy stores to maintain energy homeostasis through secretion of  endocrine hormones (25). 
Chronic overnutrition resulting in DIO puts excessive stress on this regulation, and high circulating levels 
of  free fatty acids, glucose, and amino acids result in a hypothalamus inflammatory response, analogous to 
peripheral inflammation in WAT and liver (26). Microglial cells, specialized macrophage cells in the brain, 
become activated and release cytokines that initially are protective but chronically cause hypothalamic 
dysfunction, leading to obesity and glucose intolerance (27).
Here, we investigate the effect of  cerebral EPO on the brain/hypothalamus during DIO that in turn 
mediates the EPO metabolic regulation. To this end, we used transgenic Tg21 mice that present with con-
stitutive brain-specific overexpression of  human EPO in an oxygen-independent manner and without an 
increase in EPO-stimulated erythropoiesis (28), EPO infusion in brain in WT mice, and knockout of  cerebral 
EpoR gene expression to assess the protective potential of  cerebral EPO during high-fat diet (HFD) feeding.
Results
Transgenic expression of  cerebral EPO prevents weight gain, increases energy expenditure, and improves glucose tolerance 
and insulin sensitivity in male mice. DIO was reduced in male Tg21 mice with elevated brain EPO levels. During 8 
weeks of HFD, beginning at 5 weeks of age, cumulated body weight and fat mass in male mice were markedly 
lower in Tg21 mice compared with those in WT control male mice (Figure 1, A and B). Weight gain and fat mass 
increased by 90% and 600%, respectively, in male WT mice compared with 60% and 180% in Tg21 mice, respec-
tively, with a comparable increase in lean mass (Figure 1C). In contrast, female Tg21 and WT mice did not have 
different body weight gain and fat accumulation after HFD feeding (Figure 1, D–F). Male Tg21 mice showed a 
trend toward eating more and a significantly higher energy expenditure (Figure 1, G and H).
Glucose tolerance measured during normal chow diet (NCD) and after 3 weeks of  HFD feeding was 
improved in both male and female Tg21 mice compared with WT mice (Figure 1, I, J, L, and M). More-
over, while WT and Tg21 male and female mice on NCD did not show any difference in fasting blood 
glucose levels, glucose levels were higher in WT mice during HFD feeding (0-minute time point, Figure 1, 
I, J, L, and M). Insulin levels were elevated in WT mice fed HFD, suggesting that insulin sensitivity was 
reduced after 3 weeks of  HFD, but not in Tg21 mice (Figure 1, K and N). These data suggest that, when fed 
with HFD, WT male mice were more susceptible to DIO and showed lower energy expenditure than Tg21 
male mice, while both male and female Tg21 mice showed improved glucose tolerance during NCD and 
HFD and better insulin sensitivity on HFD than WT mice.
Tg21 male mice are protected from DIO-induced hypothalamus inflammation and microglial cell activation. DIO 
is associated with chronic low-grade hypothalamus inflammation that occurs within the first few days after 
HFD feeding, induces hypothalamic activation of  microglial cells, and increases proinflammatory cyto-
kines (27). Accordingly, we quantified inflammatory cytokine marker TNF-α, microglial cell marker Iba1, 
and activated microglial cell marker CD68 to assess the EPO-regulated response in the mediobasal hypo-
thalamus (MBH) of  male mice. On NCD, the number of  TNF-α+ cells was very small, but this number was 
more pronounced in WT mice compared with Tg21 male mice (Figure 2, A and C). On HFD feeding, the 
numbers increased in both WT and Tg21 male mice and became 3-fold higher in WT animals compared 
with Tg21 animals (Figure 2, B and C). Similarly, the number of  microglial cells was higher in WT mice on 
NCD (Figure 2, A and D). With DIO, Iba1+ cells increased in both WT and Tg21 mice and became 2-fold 
higher in WT mice compared with Tg21 mice (Figure 2, B and D). Quantification of  Iba1+ staining also 
showed higher staining density in WT mice compared with Tg21 mice (Figure 2, E and F). CD68 was also 
more abundant in the MBH region of  HFD-fed WT mice compared with HFD-fed Tg21 mice (Figure 2, G 
and H). Moreover, during DIO, expression of  3 additionally analyzed inflammatory genes (Ccl2, Il6, and 
Il1β) increased markedly in the hypothalamus of  WT male mice, with little or no change in the Tg21 hypo-
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thalamus (Figure 2I). Importantly, these changes in hypothalamus inflammation are sexually dimorphic. 
In female WT and Tg21 mice, TNF-α+ and Iba1+ cell numbers were very low during NCD, with comparable 
increases during HFD feeding, and there was no significant difference in Ccl2, Il6, and Il1β relative gene 
expression in the hypothalamus (Supplemental Figure 1; supplemental material available online with this 
article; https://doi.org/10.1172/jci.insight.134061DS1).
As DIO induces rapid infiltration of  blood-derived peripheral myeloid cells into the hypothalamus (29), 
we assessed recruitment of  peripheral myeloid cells into the MBH. P2Y12 is a very specific marker for microg-
lial cells, and its expression is reduced in activated microglial cells (30). During NCD, the number of  P2Y12+ 
cells was moderately higher in male WT mice (Figure 3, A and C), while during DIO, these cells decreased in 
WT mice but increased in Tg21 mice to almost double the WT number (Figure 3, A and C). CD169 is a mark-
Figure 1. During DIO, Tg21 mice show reduced weight gain/fat mass accumulation and increased energy expenditure in male mice and improved glucose 
utilization in male and female mice. (A–F) Body weight (A and D), fat mass (B and E), and lean mass (C and F) in HFD-fed Tg21 and WT mice beginning at 5 
weeks of age in male mice (A–C) and female mice (D–F). (G and H) Daily average food intake (G) and daily energy expenditure (H) at 5–8 weeks of age on HFD 
feeding in male Tg21 and WT mice. (I–N) Glucose tolerance test (GTT) and serum insulin in males (I–K) and females (L–N) in Tg21 (red line) and WT (black line) 
mice during NCD (age, 5 weeks, I and L) and after 3 weeks of HFD (age, 8 weeks, J and M). Serum insulin measurements at the beginning (0 minutes) and end 
(120 minutes) of GTT during NCD and HFD in male (K) and female (N) mice. Each graph is representative of at least 3 independent experiments; n = 8–10 for 
each data point. For line graph, each data point represents mean ± SD. In box-and-whisker plots, bounds denote the 25th to 75th percentile, the lines repre-
sent the medians, and whiskers indicate the range from minimum to maximum values and includes outliers. **P < 0.01, ***P < 0.001 (2-way ANOVA).
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Figure 2. Reduced hypothalamus inflammatory response and microglial cell activation in Tg21 male mice compared with WT male mice. (A and 
B) Representative hypothalamic sections of age-matched (8 weeks) male WT and Tg21 mice during NCD (A) or after 3 weeks of HFD feeding (B) 
stained for the nuclear marker, DAPI; inflammatory marker, TNF-α; and microglial cell marker, Iba1. 3V, third ventricle. Scale bar: 100 μm. Original 
magnification, ×40. (C and D) Quantification of A and B to denote TNF-α+ and Iba1+ cells. (E and F) Representative fields of view in HFD-fed WT and 
Tg21 mice (scale bar: 20 μm) (E), analyzed for quantification of fluorescence intensity of Iba1 (F). (G and H) Representative hypothalamic sections 
of age-matched (8 weeks) male WT and Tg21 mice after 3 weeks of HFD feeding stained for activated microglial cell markers, CD68 and DAPI 
(scale bar: 100 μm; original magnification, ×40) (G), and quantification of CD68+ cells (H). Each image is representative of n = 8–10/group. (I) Gene 
expression of markers Ccl2, Il6, and Il1β in the hypothalamus of age-matched (8 weeks) male Tg21 and WT mice on NCD or after 3 weeks of HFD, as 
determined by quantitative RT-PCR, normalized to WT control on NCD and adjusted to Gapdh gene expression (n = 8–10/group). In box-and-whisker 
plots, bounds denote the 25th to 75th percentile, the lines represent the medians, and whiskers indicate the range from minimum to maximum 
values and includes outliers. **P < 0.01, ***P < 0.001 (2-way ANOVA).
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Figure 3. Nonactivated P2Y12+ microglial cells in male Tg21 mice are reduced under NCD and increased on HFD feeding 
but decreased in male WT mice on HFD feeding, with an increase in peripheral CD169+ cell recruitment. (A) Representative 
hypothalamic sections of age-matched (8 weeks) male Tg21 and WT mice during NCD or after 3 weeks of HFD feeding stained 
for the nuclear marker, DAPI; peripheral macrophage marker, CD169; and nonactivated microglial marker, P2Y12, in MBH. (B) 
Visualization of boxed areas from A without DAPI staining and with arrowheads pointing to CD169+ cells. (C and D) Quantifi-
cation of A. Scale bar: 100 μm. Original magnification, ×40. 3V, third ventricle. Each image is representative of n = 8–10/group. 
In box-and-whisker plots, bounds denote the 25th to 75th percentile, the lines represent the medians, and whiskers indicate 
the range from minimum to maximum values and includes outliers. **P < 0.01, ***P < 0.001 (2-way ANOVA).
 
6insight.jci.org   https://doi.org/10.1172/jci.insight.134061
R E S E A R C H  A R T I C L E
er for myeloid monocyte-derived cells recruited from the periphery and not expressed by resident microglial 
cells (31). Few or no CD169+ cells were detected during NCD; with the development of  DIO, the number of  
CD169+ cells increased in male mice, reaching 5-fold higher or more in WT mice compared with Tg21 mice 
(Figure 3, A, B, and D). Again, these changes are sex specific; in females, the number of  P2Y12+ cells was 
comparable and CD169+ staining was almost undetectable in WT and Tg21 mice (Supplemental Figure 2).
HFD-induced weight gain, glucose intolerance, and hypothalamic inflammation are regulated by endogenous phys-
iological EPO/EpoR signaling. Cerebral EPO expression in transgenic Tg21 mice is approximately 4-fold 
compared with WT controls (28). To study if  physiological EPO levels and signaling via EpoR in the brain, 
especially in neuronal cells, can regulate HFD-induced metabolic changes in mice, we knocked out EpoR 
gene expression in neuronal cell precursors. This was achieved by mating chimeric EpoR-floxed mice with 
mice containing a Cre-recombinase gene controlled by the nestin promoter (32). Glial EpoR expression was 
expected to be unchanged. Ablation of  EpoR gene expression in nestin-Cre;EpoRloxP/loxP mice was verified by 
mRNA quantification in the brain, comparing WT mice and nestin-Cre;EpoRWT/WT mice, while its splenic 
expression as well as the hematocrit levels were unaffected (Supplemental Figure 3). For all subsequent 
studies with the nestin-Cre;EpoRloxP/loxP mice, the nestin-Cre;EpoRWT/WT mice were used as controls to counter 
the off-target effects of  nestin promoter–driven Cre-recombinase expression and to ensure that the metabolic 
effects were seen due to lack of  EpoR gene and not due to nestin-Cre transgene (33–35).
During DIO, male mice deficient for cerebral EpoR (e.g., nestin-Cre;EpoRloxP/loxP mice) gained significantly 
more weight than male controls (nestin-Cre;EpoRWT/WT mice) (Figure 4A) and became more glucose intolerant 
after 4 weeks of HFD feeding (Figure 4B). Conversely, female mice lacking cerebral EpoR showed a moderate 
but significantly greater weight gain after only 2 weeks of HFD feeding and not at other time points tested (Fig-
ure 4C). Nevertheless, comparable to that in male mice, glucose tolerance was worse in female cerebral EpoR-de-
ficient mice compared with female controls (Figure 4D). HFD-induced TNF-α expression in the MBH of male 
nestin-Cre;EpoRloxP/loxP mice was also significantly higher than that in male nestin-Cre;EpoRWT/WT mice (Figure 4, E 
and F); however, Iba1+ microglial cells did not show any significant difference in cell numbers and fluorescence 
intensity between the 2 groups (Figure 4, E, G, and H). Activated microglial cells, stained with CD68 antibody, 
were more abundant in nestin-Cre;EpoRloxP/loxP mice compared with nestin-Cre;EpoRWT/WT mice (Figure 4, I and J). 
CD169+ peripheral myeloid cells were recruited more in the hypothalamus of nestin-Cre;EpoRloxP/loxP mice than in 
nestin-Cre;EpoRWT/WT mice, but P2Y12+ cells were not significantly different between the 2 groups (Figure 4, K 
and L). In summary, these studies show that, similar to EPO overexpression, endogenous physiological EPO/
EpoR signaling in the brain plays an important role in preventing HFD-induced weight gain and inflammation 
in male mice and can regulate glucose tolerance in both male and female mice.
Male Tg21 mice are protected from pituitary-adrenal activation during DIO. The hypothalamus-pituitary-adre-
nal (HPA) axis is a critical neuroendocrine control over stress response induced during DIO. The hypothal-
amus and pituitary gland function to maintain energy expenditure. Corticotropin releasing factor (CRF) 
released from the hypothalamus induces ACTH secretion from the pituitary, which in turn drives release 
of  corticosterone from the adrenal gland. The ACTH level during NCD showed a small reduction in Tg21 
mice, which increased in both WT and Tg21 mice during DIO to become 1.7-fold greater in WT mice 
compared with Tg21 mice (Figure 5A). Corticosterone levels were similar in WT and Tg21 mice during 
NCD and increased only in WT mice during DIO, becoming 2-fold greater (Figure 5B). The inflammatory 
marker C-reactive protein was higher in WT mice than in Tg21 mice during NCD, was induced in DIO 
in both WT and Tg21 mice, and remained significantly higher in WT mice (Figure 5C). This observation, 
too, was sex specific; in female WT and Tg21 mice no differences were observed in serum levels of  ACTH, 
corticosterone, and C-reactive protein during NCD or HFD (data not shown).
Fgf21 and adiponectin levels during DIO. Female mice appear to be protected from hypothalamus 
inflammation and pituitary-adrenal activation, but, similar to male mice, they exhibit glucose intol-
erance during DIO. Fgf21, a cytokine produced primarily in liver, is involved in regulation of  glucose 
metabolism and insulin sensitivity, parameters that are improved in male and female Tg21 mice during 
NCD and DIO. During NCD, Fgf21 was elevated in male and female Tg21 mice. However, after 1 and 
3 months on HFD, Fgf21 levels increased in male and female WT mice beyond the levels in Tg21 mice, 
which remained unchanged (Figure 5, D and E). Adipocytes are one main target of  Fgf21 where Fgf21 
promotes adiponectin production. During NCD, male and female Tg21 mice showed a significantly 
higher adiponectin level, although fat mass was comparable to that of  WT mice (Figure 5, F and G, 
and Table 1). Adiponectin levels increased during HFD feeding in both Tg21 and WT mice, but there 
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was a higher elevation in male and female Tg21 mice. This observation was surprising, as male WT 
mice had more fat mass (Figure 5F and Table 1); it suggests that during DIO, despite higher Fgf21 in 
WT mice (Figure 5, D and E), adiponectin levels were not concomitantly higher in these mice. On 
the other hand, Tg21 male mice and female mice showed a greater sensitivity to Fgf21, as reflected in 
adiponectin levels (Figure 5, F and G, and Table 1).
βKlotho expression in WAT and Fgf21 signaling in hypothalamus during DIO. While systemic metabolic effects 
of  Fgf21 are mediated mainly by adiponectin from WAT (36), hepatic Fgf21 can regulate glycogen synthesis 
and ketone body production (37, 38). Fgf21 can also cross the blood-brain barrier and act as a messenger 
between the liver and hypothalamus, thereby regulating CRF expression and adrenal corticosterone levels 
(39). In the presence of  the critical coreceptor βKlotho, Fgf21 binds to isoforms of  Fgf  receptor 1, 2, 3, and 4, 
leading to dimerization and autophosphorylation of  the Fgf receptor, followed by downstream activation of  
Erk1/2 that translocates and activates specific transcription factors in the nucleus. Expression of  Fgf  recep-
tors 1, 2, 3, and 4 was unchanged during NCD and after 3 months of  HFD (data not shown), while βKlotho 
expression in WAT during DIO was significantly reduced in male and female WT mice in contrast to male 
and female Tg21 mice, which showed no difference in βKlotho expression in WAT, liver, and hypothalamus 
during NCD or HFD (Figure 6, A–C). During DIO, Fgf21 in serum was higher in male and female WT mice 
(Figure 5, D and E), and on the other side of  the blood-brain barrier, we detected higher CRF expression in 
the hypothalamus in male WT mice compared with that in Tg21 mice but CRF expression was comparable in 
female WT and Tg21 mice (Figure 6, D and E). This suggested that, while Fgf21 increased in WT mice during 
DIO, it did not lead to elevated adiponectin secretion, possibly due to βKlotho downregulation in WT WAT 
compared with that in Tg21 mice. Moreover, CRF secretion from the hypothalamus was higher in male WT 
mice compared with male Tg21 mice but remained unchanged in female mice.
Intracerebroventricular EPO administration during DIO prevents weight gain, lowers blood glucose levels, and 
attenuates hypothalamic inflammation. To determine whether administration of  recombinant human EPO 
in brain is protective for DIO, 10 U/d EPO was infused continuously for 2 weeks into the lateral cerebral 
ventricle of  male mice, together with HFD feeding. Saline infusion was used as a control. EPO infusion 
reduced cumulative weight gain and fat mass from days 7 through 14 of  HFD feeding, with no significant 
effect on in lean mass (Figure 7, A–C). EPO brain infusion resulted in a modest increase in hematocrit 
at week 1 and a modest decrease at week 2 compared with saline-infused mice (Figure 7D). The week 2 
hematocrit level in EPO-infused mice was significantly lower than the week 1 level, which could possibly be 
due to a feedback from the brain through the sympathetic nervous system (40). Fasting glucose levels were 
significantly lower in male mice receiving EPO brain infusion (Figure 7E). Finally, at the end of  2 weeks 
of  EPO infusion, hypothalamic expression of  inflammatory markers IL-1α, IL-6, SOCS3, and TNF-α was 
down regulated while expression of  antiinflammatory marker IL-10 was increased (Figure 7F). These find-
ings suggest that pharmacological administration of  EPO into the brain during HFD feeding can prevent 
weight gain and hypothalamus inflammation and improve glucose tolerance.
EPO action in female Tg21 mice is blunted by estrogen’s protective effect against DIO. Male mice are more sus-
ceptible to DIO than female mice (41), and obesity-related hypothalamic inflammation affects male but not 
female rodents (42–44). Similarly, microglial cell response during HFD feeding is sexually dimorphic, with 
male mice presenting more accumulation and activation of  microglial cells in MBH (42). Moreover, the 
metabolic response of  EPO protection from DIO is sex specific and is observed predominantly in male mice 
(18). Here, we found that inflammatory stress in female WT and Tg21 hypothalamus was comparable during 
Figure 4. Knockout of the EpoR gene in neuronal cells in mice increased weight gain, glucose intolerance, hypothalamus inflammation, and myeloid 
cell recruitment in the MBH. (A and C) Weight gain during HFD feeding from 5 to 13 weeks of age. (B and D) Glucose tolerance test was carried out 
after 4 weeks of HFD feeding at age 9 weeks. (E–H) Representative hypothalamic sections of age-matched (8 weeks) male nestin-Cre;EpoRWT/WT and 
nestin-Cre;EpoRloxP/loxP mice after 3 weeks of HFD feeding stained for the nuclear marker, DAPI; inflammatory marker, TNF-α; microglial cell marker, 
Iba1 (E). (F and G) Quantification was done for TNF-α+ and Ibal1+ cells. (H) Representative fields of view in HFD-fed male nestin-Cre;EpoRWT/WT and 
nestin-Cre;EpoRloxP/loxP mice, analyzed for quantification of fluorescence intensity of Iba1. (I–J) Male nestin-Cre;EpoRWT/WT and nestin-Cre;EpoRloxP/loxP 
mice after 3 weeks of HFD feeding were also stained for activated microglial cell markers, CD68 and DAPI, in the MBH, and (I) representative images 
are shown. (J) Quantification was done for CD68+ cells. (K and L) Representative images from CD169 and P2Y12 staining of hypothalamic sections from 
male nestin-Cre;EpoRWT/WT and nestin-Cre;EpoRloxP/loxP mice after 3 weeks of HFD feeding, and visualization of boxed areas without DAPI staining and 
arrowheads pointing to CD169+ cells (K). Quantitative analysis results of P2Y12+ and CD169+ cells (L). Scale bar: 20 μm (H); 100 μm (E, I, and K). Original 
magnification, ×40 (except in H, ×80). 3V, third ventricle. Each image is representative of n = 8–10/group. For line graph, each data point represents 
mean ± SD. In box-and-whisker plots, bounds denote the 25th to 75th percentile, the lines represent the medians, and whiskers indicate the range from 
minimum to maximum values and includes outliers. *P < 0.05, **P < 0.01, ***P < 0.001 (2-way ANOVA).
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HFD feeding and that EPO did not elicit an additional protective effect against DIO in female mice (Supple-
mental Figures 1 and 2). To assess the protective effect of  estrogen in DIO, we used ovariectomized (OVX) 
and sham controlled female mice undergoing a 6-week HFD feeding period. Body weight gain and fat mass 
after 3 and 6 weeks were greatest in OVX WT mice (Figure 8, A and B), suggesting that estrogen plays a 
dominant role in preventing DIO in female mice and estrogen reduction in OVX mice results in significantly 
higher body weight and fat mass gain during HFD feeding. Furthermore, EPO overexpression in the brain 
protects against DIO in OVX Tg21 mice with loss of  estrogen protection compared with OVX WT mice.
Assessment of  direct inflammatory effects in MBH of  WT and Tg21 mice subjected to ovariectomy 
and HFD feeding showed that reduction of  estrogen production in OVX WT mice increased TNF-α+ cells 
Figure 5. Tg21 mice had lower serum levels of ACTH, corticosterone, C-reactive protein, and Fgf21 but higher adiponectin levels during devel-
opment of DIO. (A–C) Serum levels of ACTH (A), corticosterone (B), and C-reactive protein (C) in age-matched (5 months) male Tg21 and WT mice 
during NCD or after 3 months of HFD feeding. (D and E) Serum levels of Fgf21 in male (D) and female (E) age-matched (5 months) Tg21 and WT 
mice during NCD or after 1 month or 3 months of HFD feeding. (F and G) Fat mass versus serum adiponectin levels in male (F) and female (G) age-
matched (5 months) Tg21 and WT mice during NCD or after 3 months of HFD feeding. In box-and-whisker plots, bounds denote the 25th to 75th 
percentile, the lines represent the medians, and whiskers indicate the range from minimum to maximum values and includes outliers. *P < 0.05, 
**P < 0.01, ***P < 0.001 (2-way ANOVA), n = 6–8/group.
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and Iba1+ cells in hypothalamic sections, indicating an increase in inflammatory response and microglial 
cell number compared with sham WT mice (Figure 8, C and D). In contrast, OVX Tg21 mice with elevated 
brain EPO did not show any such increase compared with sham Tg21 mice (Figure 8, C and D). Female 
sham WT and sham Tg21 mice did not show any difference in TNF-α or Iba1 staining. These findings 
suggested that estrogen protection for DIO includes concomitant reduced hypothalamic inflammation and 
that loss of  estrogen production in OVX female mice with HFD feeding increased hypothalamic inflamma-
tion. However, female OVX Tg21 mice with elevated brain EPO did not exhibit a hypothalamus inflamma-
tory response during HFD feeding due to the EPO antiinflammatory effect that was also seen in Tg21 male 
mice with elevated brain EPO (Figure 2) and after intracerebroventricular EPO administration (Figure 7).
Discussion
The hypothalamus plays a master role in coordinating food intake and energy expenditure, and hormones, 
such as leptin and insulin, act as messengers between the periphery and hypothalamus. These hormones 
inform about peripheral energy stocks and trigger physiological responses in hypothalamus, controlling 
hunger, glucose metabolism, and thermogenesis. We previously found that EPO treatment in WT mice 
decreases body weight and fat mass by increasing energy expenditure (12, 15) and can directly activate 
POMC expression by inducing the STAT3 signaling pathways after subcutaneous administration of  recom-
binant human EPO at 3000 U/kg body weight dose (13). Similarly, intraperitoneal administration of  EPO 
at 5000 U/kg body weight has been shown to be neuroprotective in rodent models of  focal brain ischemia 
(45) and schizophrenia (46). These studies show that EPO administered at such doses can cross the blood-
brain barrier and elicit neuroprotective as well as metabolic effects. Similarly, endogenous physiological 
EPO/EpoR signaling also regulates metabolism, as mice lacking the EpoR gene in nonhematopoietic tis-
sues exhibit fat gain, glucose intolerance, and insulin resistance, resulting from low energy expenditure 
that is primarily due to loss of  endogenous EPO response in WAT and hypothalamus (12). These mice 
presented with high plasma ACTH concentration due to higher ACTH secretion from anterior pituitary 
(14). These nonerythropoietic EPO activities were attributed to EPO response in multiple tissues, including 
the brain. Here, we focused on elucidating EPO’s brain-specific role that may contribute to the metabolic 
response, especially during DIO. As a model with elevated brain EPO without increase in EPO-stimulated 
erythropoiesis, we used Tg21 mice overexpressing EPO in the brain and WT mice with intracerebral ven-
tricular EPO pumps. Increased cerebral EPO levels prevented weight and fat gain during HFD feeding in 
male mice, and male Tg21 mice exhibited higher energy expenditure. Absence of  EpoR in the brain and oth-
er nonhematopoietic cells led to reduced locomotor activity and energy expenditure, while EPO treatment 
in WT mice increased these parameters (12). Furthermore, elevated brain EPO in Tg21 mice or in mice 
administered high-dose EPO increased maximal aerobic capacity and time to exhaustion during exercise 
(47), underlining the widespread effect of  cerebral EPO on physical energy expenditure. Intracerebroven-
tricular administration of  EPO has been previously shown to be protective against cortical infarction, loss 
of  thalamic neurons, behavioral deficits, and reperfusion injury in a rodent model of  permanent middle 
cerebral artery occlusion (48–50). Here, our findings show that such continuous EPO infusion can also 
be protective against DIO and related glucose intolerance and hypothalamic inflammation. We detected a 
small but significant decrease in hematocrit in EPO-infused mice at week 2, which could possibly be due 
to feedback regulation mediated by the high EPO levels in the brain (40). Previous studies have shown that 
the sympathetic nervous system and its constituents, the sympathetic nerve fibers and neural crest–derived 
cells, are critical regulators of  hematopoietic stem cell behavior during homeostasis and stress (51–53).
Table 1. Fat mass and serum adiponectin levels in male and female WT and Tg21 mice
Male WT mice Male Tg21 mice P value Female WT mice Female Tg21 mice P value
NCD Fat mass (g) 2.21 ± 0.26 2.00 ± 0.21 0.192 2.05 ± 0.13 2.06 ± 0.34 0.976
NCD Adiponectin (ng/ml) 363.44 ± 41.82 495.58 ± 49.62 0.002 423.73 ± 32.45 659.11 ± 176.13 0.035
HFD Fat mass (g) 22.71 ± 1.47 16.8 ± 1.48 1.72 × 10–5 20.42 ± 2.81 17.01 ± 3.69 0.0001
HFD Adiponectin (ng/ml) 1851.78 ± 455.79 2926.15 ± 481.02 0.002 1477.05 ± 603.38 2742.66 ± 255.37 0.067
Fat mass and serum adiponectin levels in male and female age-matched (5 months) Tg21 and WT mice during NCD or after 3 months of HFD feeding 
(n = 6–8/group) (mean ± SD). Statistical significance was tested by 2-way ANOVA, and significant P values are shown in bold. 
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We observed that, in male Tg21 mice, reduced body weight gain and fat mass accumulation was 
accompanied by improved glucose metabolism and insulin sensitivity during both NCD and HFD 
feeding. Interestingly, improved glycemic control in Tg21 mice was seen in both male and female mice, 
possibly regulated by Fgf21 and adiponectin action. Fgf21 is a hormone made primarily in the liver 
and acts as a key metabolic regulator, essential for maintaining glucose homeostasis (54). In mice, 
Fgf21 is induced at the transcriptional level and released from liver in response to nutritional stresses, 
such as HFD feeding (55). Similarly, in humans, circulating FGF21 levels correlate positively with 
BMI (56), and plasma FGF21 is elevated in obese and diabetic humans (57). This suggests that during 
obesity Fgf21 fails to exert its expected effects on glucose homeostasis, which is affected by several 
factors, including decreased expression of  Fgf21 coreceptor (58). Our findings show that increased 
Fgf21 during DIO in WT mice was accompanied by lower adiponectin production from WAT, possibly 
due to downregulation of  the Fgf21 coreceptor βKlotho. Adiponectin, a major downstream effector of  
Fgf21, contributes to the metabolic benefits of  Fgf21 in both liver and skeletal muscles (36). Although 
Figure 6. During DIO, Fgf21 coreceptor βKlotho mRNA expression was reduced in WAT of male and female WT mice while Fgf21 signaling was activated 
in hypothalamus of male WT mice. (A–C) Quantitative mRNA measurements of βKlotho in WAT (A), liver (B), and hypothalamus (C) in age-matched (5 
months) male and female Tg21 and WT mice during NCD or after 3 months of HFD feeding. Gene expression is presented as relative to male or female WT 
mice on NCD and adjusted for Gapdh mRNA expression. (D and E) Gene expression of CRF in the hypothalamus of male (D) and female (E) Tg21 and WT 
mice (age 5 months) after 3 months of HFD feeding determined by quantitative RT-PCR, normalized to WT control and adjusted to Gapdh gene expression 
(n = 6–8/group). In box-and-whisker plots, bounds denote the 25th to 75th percentile, the lines represent the medians, and whiskers indicate the range 
from minimum to maximum values and includes outliers. ***P < 0.001 (2-way ANOVA).
 
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.134061
R E S E A R C H  A R T I C L E
this effect is seen in both male and female mice, the hypothalamus response of  Fgf21 with respect to 
CRF expression showed sexual dimorphism without any difference in Fgf21 receptor and βKlotho 
expression. Higher CRF expression in the hypothalamus of  male WT mice (Figure 6D) could ulti-
mately cause higher ACTH and corticosterone levels in the serum (Figure 5, A and B). Pharmacologic 
studies have also revealed that Fgf21 results in elevated blood corticosterone in mice (59).
Excess consumption of  HFD results in hypothalamus inflammation analogous to other peripher-
al tissues, including WAT, liver, and skeletal muscles (26). Hypothalamic inflammation is one of  the 
major pathways by which overnutrition can cause obesity. Disruption of  inflammatory molecules has 
been shown to protect against DIO. For example, ablation of  IKKβ in AgRP neurons (60), knockout of  
MyD88 in the CNS (61), or inhibition of  TLR4 and TNF-α in the hypothalamus (62) produce benefi-
cial metabolic effects in HFD-fed mice. The inflammatory effect is accompanied by infiltration by bone 
marrow–derived CD169+ myeloid cells that is critical for causing “microgliosis” in MBH and metabolic 
dysfunction (63). To disrupt the EPO response in the brain, we targeted deletion of  EpoR in nestin+ cells, 
including their progeny, that includes neurons but not microglial cells (64, 65). Our attempts at EpoR 
gene knockout in all cell types by viral Cre administration in EpoRloxP/loxP mice resulted in nonspecific 
recombinase action, even in WT mice. Therefore, the effects seen in nestin-Cre:EpoRloxPloxP mice could 
only be contributed by physiological EPO function in neuronal cells. Our findings in male Tg21 mice 
and in male WT mice with intracerebroventricular EPO infusion directly link EPO protection and low-
er hypothalamus inflammation. In mouse WAT, peripheral EPO treatment during DIO prevents WAT 
inflammation, reduces macrophage infiltration, and improves glucose tolerance and insulin sensitivity 
Figure 7. Intracerebroventricular administration of EPO protected mice from 
DIO and reduced fasting blood glucose and inflammation, without affecting 
hematocrit. (A–C) Mice at age 5 weeks were infused with recombinant human 
EPO or saline and fed HFD for 2 weeks. Cumulative weight gain (A), fat mass 
(B), and lean mass (C) were measured at indicated time points. (D and E) At the 
end of weeks 1 and 2, hematocrit (D) and blood glucose (E) were measured for 
EPO- or saline-infused mice. (F) Gene expression of inflammatory markers in 
the hypothalamus at the end of 2 weeks of EPO-infused mice, as determined by 
quantitative RT-PCR, normalized to saline control and adjusted to Gapdh gene 
expression. In box-and-whisker plots, bounds denote the 25th to 75th percentile, 
the lines represent the medians, and whiskers indicate the range from minimum 
to maximum values and includes outliers. *P < 0.05, **P < 0.01, ***P < 0.001 
(2-way ANOVA), n = 6–8/group.
 
1 3insight.jci.org   https://doi.org/10.1172/jci.insight.134061
R E S E A R C H  A R T I C L E
(6). Male Tg21 mice had reduced levels of  the inflammatory marker C-reactive protein in serum, during 
both NCD and HFD feeding, suggesting that peripheral inflammation is also lower in Tg21 mice inde-
pendent of  weight and fat mass difference.
EPO regulation of  body weight and fat mass in female mice during HFD feeding is minimal but is 
readily apparent in OVX mice and is masked in OVX mice with estradiol supplementation (18). Our pres-
ent studies were carried out in randomly cycling females, as random cycling better resembles a chronic 
condition, such as DIO, in cycling females. In addition, previous studies done in cycling female mice have 
not found any significant difference in inflammatory cytokines throughout the estrous cycle (66), and the 
HPA axis response to endotoxins does not vary with different stages of  the normal estrous cycle (67). 
Moreover, female mice have been shown to be resistant to hypothalamic inflammation and DIO through 
estrogen effects, and ovariectomy can eliminate these protective effects (41–43). Results from female Tg21 
Figure 8. Ovariectomized WT mice but not Tg21 mice lose the protective effect against DIO. (A and B) Female WT and Tg21 mice underwent ovariecto-
my (OVX) or sham surgery (Sham) at 12 weeks of age and were fed HFD for the next 6 weeks. Body weight (A) and fat mass (B) were measured every 3 
weeks. (C) Representative hypothalamic sections after 6 weeks of HFD stained for the nuclear marker, DAPI; inflammatory marker, TNF-α; and activated 
microglial cell marker, Iba1, in MBH of sham or ovariectomized Tg21 and WT mice. Scale bar: 100 μm. Original magnification, ×40. 3V, third ventricle. (D) 
Quantitative analysis to show TNF-α+ and Iba1+ cells. Each image is representative of n = 6–8/group. In box-and-whisker plots, bounds denote the 25th to 
75th percentile, the lines represent the medians, and whiskers indicate the range from minimum to maximum values and includes outliers. *P < 0.05, **P 
< 0.01, ***P < 0.001 (2-way ANOVA).
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mice also suggest that estrogen can elicit the maximal protective effect against hypothalamic inflammation 
and DIO and that EPO overexpression in brain is not additionally beneficial in female mice. However, loss 
of  estrogen as occurring in OVX WT mice results in increased hypothalamic inflammation on HFD feed-
ing, and the protective effect of  elevated brain EPO for hypothalamic inflammation in DIO is demonstrated 
in OVX Tg21 mice. An effect of  estrogen on EPO-regulated functions in the brain and carotid bodies has 
been already postulated in the past using the same and similar EPO-overexpressing mouse models (68, 69). 
It was shown that cerebral EPO mediates the neuronal control of  the ventilatory response to hypoxia in a 
sex-dependent manner and that estradiol interferes with EPO’s effect on this response (70). Taken together, 
all these findings strongly support the evidence that EPO and estrogen may be functioning through similar 
mechanisms regulating metabolism and ventilation both in the brain and in the periphery.
Evidence of  decreased expression of  EPO during aging may be relevant to the development of  neuroin-
flammation and neurodegeneration throughout lifetime. Population-based studies have previously shown 
an association between anemia and neurodegenerative disorders, such as Alzheimer’s and Parkinson’s 
disease (71, 72). This association is most evident when anemia onset occurs 20–29 years before Parkin-
son’s disease (73). Irregular erythrocyte morphology and eryptosis has also been found to be enhanced in 
patients with Parkinson’s disease (74).
The observations reported here might have a widespread clinical effect on future therapies targeting 
anemia. So far, EPO and its derivatives have been used to enhance erythropoiesis. EPO itself  is controlled 
in an oxygen-dependent manner via the cellular oxygen-sensing axis HIF-2/PHD2 (75). At present, new 
inhibitors of  PHD2 that in turn stabilize the α-subunit of  HIF-2 and subsequently increase transcription 
of  the EPO gene (76) are in the process of  being commercialized. As these small compounds will most 
probably cross the blood-brain barrier, it is conceivable that they will inhibit the PHD2 activity in neuronal 
cells too, ultimately increasing cerebral EPO production. If  so, elevated EPO levels in the brain might have 
an effect on glucose metabolism and hypothalamic metabolism and inflammation, as shown here. A limita-
tion of  the current study is that the Tg21 mice, which have chronic overexpression of  human EPO cDNA, 
can develop adaptive changes that could mask some potential neuroendocrine effects of  EPO during DIO. 
These can be further investigated by studying a conditional overexpression system, which can eliminate the 
scope of  any possible adaptive changes in Tg21 mice.
In summary, our studies demonstrate involvement of  EPO/EpoR signaling in the brain and, par-
ticularly, in the hypothalamus in metabolic regulation during NCD and DIO. EPO overexpression in 
brain improves glucose utilization in male and female mice, possibly through Fgf21 and adiponec-
tin regulation. On the other hand, EPO can exert an antiinflammatory response during DIO in male 
mice that effectively reduces microglial activation and recruitment of  peripheral myeloid cells in the 
hypothalamus. In female mice, the antiobesity and hypothalamus antiinflammatory estrogen effects 
are predominant and the antiinflammatory effect of  EPO is minimal, and the absence of  estrogen’s 
protective effect (via ovariectomy) allows for this EPO response. This also parallels EPO’s regulation 
of  weight and fat gain that we saw in male Tg21 mice but not in female Tg21 mice, which can only be 
seen in female mice after ovariectomy. These findings on activity associated with elevated EPO without 
increased EPO-stimulated erythropoiesis reveal a previously unrecognized EPO function in the brain 
that controls metabolism via central and peripheral action.
Methods
Mouse models. Tg21 mice, overexpressing PDGFβ promoter–driven human EPO (77), and WT mice 
(National Cancer Institute/Charles River Laboratories) were on a C57BL/6 background. The Tg21 
mice were bred to homozygosity and verified by crossing with WT mice to check for all heterozygous 
pups. Deletion of  the EpoR gene in neuronal cell precursors was achieved by nestin promoter–driven 
Cre recombinase expression in EpoRloxP/loxP mice (22). The nestin-Cre mice, on a C57BL/6 background, 
were purchased from The Jackson Laboratory (stock no. 003771). EpoRloxP/loxP mice were from a C57/129 
hybrid mouse strain but were backcrossed onto a pure C57BL/6 background for at least 7 generations 
in our lab (78). Animals were housed in a specific pathogen–free and thermostable environment, with a 
12-hour light/dark cycle and free access to food (NIH-31, 14% kcal/fat, 3.0 kcal/g, Teklad Diets) and 
water. For DIO, mice were fed HFD (60 kcal% fat, 34.9% crude fat, 5.24 kcal/kg, Research Diets Inc.). 
Body composition, glucose tolerance, food intake, activity, hematocrit, and serum cytokine levels were 
assessed, and select tissues were harvested for gene and protein expression level.
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Immunofluorescence. Anesthetized mice were perfused with saline and 4% paraformaldehyde in 100 
mM phosphate buffer, and brains were dissected, postfixed in the same fixative overnight (4°C), and 
immersed successively in 10%, 20%, and 30% sucrose for 3 consecutive nights (4°C). Hypothalami were 
separated from other regions, embedded in optimal cutting temperature compound, immediately frozen 
on dry ice, and stored at –80°C. Hypothalamic coronal sections (10-μM thick, 2 sections per slide) across 
the MBH were cut on a cryostat, blocked for 1 hour with 5% normal goat serum and 0.3% Triton X-100, 
and incubated with primary antibodies overnight at 4°C. Primary antibodies used were as follows: Iba1 
(NCNP24, Wako Chemicals), TNF-α (ab1793, Abcam), CD169 and CD68 (MCA884 and MCA1957, 
respectively, Bio-Rad), and P2Y12 (AS-55043A, AnaSpec). Alexa Fluor–conjugated secondary antibod-
ies were used for immunofluorescence microscopy. Sections were mounted with ProLong Gold antifade 
reagent with DAPI (Cell Signaling Technology) to identify cell nuclei. A Zeiss LSM 780 confocal scan 
head (Carl Zeiss Microscopy) mounted on a Zeiss AxioObserver.Z1 microscope, running ZEN 2.3 soft-
ware, was used to acquire images at magnifications specified in the figure legends. The number of  stain+ 
cells was counted in 4–6 microscopic fields of  view of  equal size in each sample. Cells were evaluated for 
the presence of  a labeled nucleus, and immunofluorescently labeled cells were counted manually from 
5–6 matched sections within prespecified regions of  interest in the MBH using ImageJ software (NIH). 
For immunofluorescent intensity measurement using ImageJ, cells of  interest in a field were selected 
using the drawing/selection tools. Area size, integrated density, and mean gray value were measured 
for immunofluorescent signal and background region. Corrected cell fluorescence intensity was mea-
sured by subtracting the product of  area and mean fluorescence of  background reading from integrated 
density. This was repeated for every cell in the field of  view and repeated for 4–6 fields of  view per slide 
and matched sections in the subsequent slide of  same group. Data were then pooled for each group and 
graphically represented after statistical analysis.
Intracerebroventricular EPO infusion. Under isoflurane anesthesia, each mouse received a cannula (Brain 
Infusion Kit 3, Alzet) implanted over the appropriate stereotaxic coordinates: midline, 1.00 mm; antero-
posterior, 0.34 mm; dorsoventral, 2.30 mm. The cannula was fixed onto the skull with dental cement and 
connected via polyethylene tubing to a subcutaneously implanted 14-day osmotic minipump (Alzet, model 
2006). Minipumps were filled with either recombinant human EPO (Epogen, Amgen) or saline.
Body composition and glucose tolerance test. Body weight was measured using the same balance by the same 
person. Body composition for fat mass and lean mass were measured using an EchoMRI 100H instrument 
(Echo Medical Systems) in conscious, immobilized mice. For glucose tolerance test, mice fasted overnight 
were injected with glucose (2.0 g/kg). Blood glucose levels were measured before (0 minute) and up to 120 
minutes after injection from tail vein bleeds (Alphatrak 2 glucometer, Zoetis). For determination of  insulin 
secretion in response to glucose stimulation, 30 μl blood was collected before (0 min) and after 120 minutes 
of  glucose stimulation; then, serum was prepared and flash frozen in liquid nitrogen for later assessment.
Food intake, activity, and energy expenditure. Mice were allowed to adapt to individual housing for 2 weeks, 
and food and water were provided ad libitum. Food intake was then measured for 3 weeks. Energy expen-
diture was calculated using the energy balance method previously described (79). In brief, caloric energy 
intake was calculated from food intake, and change in body energy stores was calculated at 9.4 kcal/g of  
body fat and 1.0 kcal/g of  fat-free mass. Energy expenditure was determined as the difference of  caloric 
energy intake and sum of  change in body energy store.
Real-time quantitative PCR. Total RNA was extracted using the RNeasy Lipid tissue mini kit (74804, 
Qiagen) according to manufacturer’s instructions and reverse-transcribed with MuLVReverse Transcrip-
tase (N8080018, Applied Biosystems). Transcript levels were measured using the semiquantitative real-
time PCR on Quantstudio 7 Flex system (Applied Biosystems) using SYBR green detection of  ampli-
cons. Gene-specific primer sequences were as follows (forward and reverse, respectively): Ccl2 Fwd: 
CAGATGCAGTTAACGCCCCA, Rev: TGAGCTTGGTGACAAAAACTACAG; Il6 Fwd: AGCCA-
GAGTCCTTCAGAGAGAT, Rev: GAGAGCATTGGAAATTGGGGT; Il1b Fwd: TGCCACCTTTT-
GACAGTGATG, Rev: TGATGTGCTGCTGCGAGATT; Il1a Fwd: AGGGAGTCAACTCATTGGCG, 
Rev: TGGCAGAACTGTAGTCTTCGT; Il10 Fwd: GCCAGAGCCACATGCTCCTA, Rev: TTTCCGA-
TAAGGCTTGGCAAC; Socs3 Fwd: TAGACTTCACGGCTGCCAAC, Rev: CGGGGAGCTAGTC-
CCGAA; TNFa Fwd: TAGCCCACGTCGTAGCAAAC, Rev: ACAAGGTACAACCCATCGGC; CRF 
Fwd: GGCATCCTGAGAGAAGTCCC, Rev: TGTTAGGGGCGCTCTCTTCT; Gapdh Fwd: CCCTTA-
AGAGGGATGCTGCC, Rev: TACGGCCAAATCCGTTCACA.
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Serum sample collection and cytokine measurements. Blood samples were collected by mandibular bleed-
ing between 8 AM and 9 AM. For serum preparation, blood was allowed to clot for 20–30 minutes at 
room temperature and then centrifuged at 2000 g for 20 minutes. Mice were fasted overnight before Fgf21 
measurements. ELISA based assays were used to measure ACTH (RK-001-21, Phoenix Pharmaceuticals), 
corticosterone (ADI-900-097, Enzo Life Sciences), C-reactive protein (ab157712, Abcam), and Fgf21 and 
Adiponectin (MF2100 and MRP300, R&D Systems). Insulin was measured in serum samples obtained 
during glucose tolerance test by ELISA (90080, Crystal Chem). 
Ovariectomy. Bilateral ovaries were removed from female mice at 11 weeks of  age as previously described 
(18). Sham surgery was also carried out in age-matched mice. Animals were allowed 1 week for recovery 
and depletion of  endogenous estrogen in OVX mice and then put on HFD from 12 to 18 weeks of  age.
Statistics. Data were analyzed using 2-way ANOVA for repeated measures between mouse groups. Post 
hoc comparison were made by Student’s t test (2-tailed) for continuous variables. A χ2 or Fisher’s exact test 
was used for nominal variables, as appropriate followed by Bonferroni correction for multiple comparisons. 
P values of  less than 0.05 were considered significant.
Study approval. All animal protocols followed the NIH guidelines and had institution Animal Care and 
Use Committee approval (ACUC of  the National Institute of  Diabetes and Digestive and Kidney Diseases, 
NIH, Bethesda, MD, USA).
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